Company
(location)

Partner
(location)

Amt.
(M)

Details

Date

TOTAL: $107M (Year to Date: $991.27M)

Advinus Therapeutics Ltd. (Pune, India)

Takeda Pharmaceutical Co. Ltd. (Osaka, Japan)

$3

In recognition of a second milestone in its research and development collaboration; Advinus is responsible for carrying out all the research required to identify candidate molecules for clinical development in several therapeutic areas while Takeda is responsible for the development and commercialization of these candidates

11/7/14

Genvec Inc. (Gaithersburg, Md.)

Novartis AG (Basel, Switzerland)

$3

For the development of treatments for hearing and balance disorders; Novartis has dosed the first patient in a clinical study to assess the safety, tolerability, and efficacy of intra-labyrinthine CGF166 in patients with severe hearing loss

11/7/14

Intra-Cellular Therapies Inc. (New York)

Bristol-Myers Squibb Co. (New York)

$1.5

For enrolling one of two planned phase III studies of ITI-007 to treat acutely exacerbated schizophrenia

11/26/14

Ironwood Pharmaceuticals Inc. (Cambridge, Mass.)

Astellas Pharma Inc. (Tokyo)

$15

For Astellas' enrollment of the first patient in a randomized, double-blind, placebo-controlled phase III trial of linaclotide in adult patients with irritable bowel syndrome with constipation in Japan

11/21/14

Isis Pharmaceuticals Inc. (Carlsbad, Calif.)

Glaxosmithkline plc (London)

$5

Related to the designation of the antisense drug ISIS-GSK5Rx as a development candidate to treat an undisclosed ocular disease

11/4/14

Isis Pharmaceuticals Inc. (Carlsbad, Calif.)

Astrazeneca plc (London)

$7.5

For the advancement of ISIS-STAT3Rx (AZD9150), in patients with advanced cancers

11/7/14

Isis Pharmaceuticals Inc. (Carlsbad, Calif.)

Biogen Idec Inc. (Cambridge, Mass.)

$10

Following the initiation of investigational new drug-supporting studies of ISIS-BIIB3Rx, a recently identified development candidate designed to inhibit an undisclosed target to treat a neurodegenerative disease

11/7/14

Isis Pharmaceuticals Inc. (Carlsbad, Calif.)

Biogen Idec Inc. (Cambridge, Mass.)

$27

For starting a pivotal phase III study evaluating ISIS-SMNRx in approximately 120 non-ambulatory children

11/26/14

Onxeo SA (Paris)

Spectrum Pharmaceuticals Inc. (Henderson, Nev.)

$25

Related to the approval of Beleodaq (belinostat) by the FDA for treating patients with relapsed or refractory peripheral T-cell lymphoma

11/14/14

PTC Therapeutics Inc. (South Plainfield, N.J.)

Roche AG (Basel, Switzerland)

$10

For the initiation of a phase Ib/IIa study in adult and pediatric patients

11/20/14


Notes

Currency conversions are based on exchange rates at the time of the deal.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

This chart includes only biotech companies that develop therapeutics.

ND = Not disclosed.